Quant Biomarkers is a science- and data-driven diagnostics company focused on next-generation biomarker solutions in Cardio-Kidney-Metabolic (CKM) diseases, enabling earlier detection, better risk prediction, treatment monitoring, and more personalized patient care. CKM diseases, like diabetes and hypertension, affects >40% of the general population and those with kidney injury mostly died much earlier due to complications. Both clinicians and pharma lack reliable tools to identify, stratify, and manage early kidney injury patients, as well as to develop and monitor new nephroprotective therapies. We are developing a groundbreaking urinary biomarker test, RenoRisk™, that is expected to detect early kidney injury 3-6 years before traditional biomarkers, such as reduced eGFR or microalbuminuria. The test enables a timely window for nephroprotective interventions (like SGLT2i, GLP-1) and can also monitor treatment effect without time lag. It includes a product for automatic laboratory workflows and a product for point-of-care or home use. With proprietary lab data from RenoRisk™, we are also developing an AI-powered predictive software for more accurate kidney disease risk stratification, monitoring and management.

Quant Biomarkers

Org chart

Teams

Offices